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Abstract
Background: The knowledge regarding myocardial alterations in patients with obstructive 
sleep apnea syndrome (OSAS) in the absence of any known cardiovascular disorders inclu-
ding hypertension is limited. The aim of this study was to assess the early alterations of left 
ventricular (LV) functions caused by OSAS before the development of hypertension and other 
cardiovascular manifestations of OSAS.
Methods: Eighty consecutive patients who underwent polysomnography (PSG) were enrolled 
in the study. Patients with hypertension, diabetes mellitus or any other known cardiac diseases 
were excluded from the study. Subjects were separated into two groups by their apnea/hypopnea 
index (AHI) (group 1: AHI < 15, and group 2: AHI ≥ 15). Fourty-three patients with normal 
polysomnographic examination or mild OSAS (group 1) and 37 patients with moderate to 
severe OSAS (group 2) were compared. After PSG examination, LV functions were assessed 
by using the conventional and tissue Doppler echocardiographic methods.
Results: The mean age was similar between the groups. The ratio of male patients was higher 
in group 2 (male/female: 31/12 in group 1 vs. 34/3 in group 2, p = 0.04). Body mass index 
was higher in group 2 (p = 0.05). Conventional echocardiography showed that interventricular 
septum thickness was 9.5 ± 1.1 mm in group 1, and 10.5 ± 1.4 mm in group 2 (p = 0.02). 
Mean left atrial diameter was 35.6 ± 4.1 mm in group 2, and 33.8 ± 3.1 mm in group 1 (p = 0.04). 
Ratio of early to late transmitral diastolic velocities was lower in group 2 (p = 0.01), indicating 
that impairment of diastolic function was more frequent in moderate to severe OSAS patients. 
Tissue Doppler echocardiography showed that early diastolic myocardial velocity was lower in 
group 2 (21.1 ± 5.6 cm/s in group 1 vs. 18.3 ± 5.3 cm/s in group 2, p = 0.01). 
Conclusions: Left ventricular diastolic dysfunction, LV hypertrophy and left atrial dilatation 
occur in patients with OSAS even before the development of hypertension and other cardiova-
scular diseases. (Cardiol J 2013; 20, 5: 519–525)
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Introduction
Obstructive sleep apnea syndrome (OSAS) is 
a respiratory disease characterized by recurrent 
complete or partial obstruction of upper respiratory 
tract with accompanying intermittent hypoxemia 
and reactive waking reactions during sleep. Chro-
nic intermittent hypoxemia during respiratory 
events may result in cardiovascular (CV) disorders 
by causing autonomic dysfunction [1, 2], endothe-
lial dysfunction [3], oxidative stress, intrathoracic 
pressure variations [3, 4], metabolic dysregulation 
[5, 6] and inflammation [3, 5].
Previous studies have shown the relation-
ship between OSAS and cardiac arrhythmias and 
conduction abnormalities [2, 7]. The Sleep Heart 
Health study group has shown a 2.38-fold increase 
in the risk of heart failure in patients with OSAS, 
independent from other risk factors [8]. 
The most convenient and reliable method 
to determine left ventricular (LV) functions is 
echocardiographic examination. Alterations of the 
systolic and diastolic functions of the LV may be 
determined earlier, and they can be quantitatively 
assessed with tissue Doppler echocardiography.
The purpose of this study was to assess the 
early alterations of LV functions before the deve-
lopment of hypertension and CV manifestations of 
OSAS by using the conventional and tissue Doppler 
echocardiographic methods.
Methods
Eighty patients (65 men and 15 women, mean 
age 44.1 ± 9.4 years) presenting to the sleep 
laboratory of Çukurova University Neurology 
Department with the complaints of excessive 
daytime sleepiness and snoring who completed 
full-night polysomnography (PSG) were enrolled 
in the study. Patients with hypertension, diabetes 
mellitus or any known heart disease were excluded 
from the study. 
Blood samples were collected from all patients 
after 12-hour fast period in the day of PSG. In ad-
dition to complete blood count and biochemistry 
including lipid profile, homocysteine, hs-C-reactive 
protein (CRP), B-type natriuretic peptide (BNP), 
and fibrinogen levels were measured.
Sleep study
All patients were admitted to the sleep cli-
nic with the complaints of excessive daytime 
sleepiness and snoring, and they were planned 
to undergo full-night PSG. Full-night PSG was 
performed using a computerized system (Kommet, 
Grass telefactor) and the following parameters 
were recorded: electrooculogram (2 channels), 
electroencephalogram (4 channels), sub-mental 
muscle electromyogram (2 channels), anterior 
tibial muscle electromyogram for both legs (2 
channels), electrocardiogram (1 channel), airflow 
(oro-nasal pressure adjusted cannula), chest and 
abdominal movements respiratory inductance 
plethysmography (2 channels), and arterial oxy-
hemoglobin saturation with finger-probe pulse 
oximetry (SaO2: 1 channel). Records were taken 
at 10 mm/s sweep rate. Sleep stages were scored 
according to the Rechtschaffen and Kales [9] 
standard criteria. Apnea was defined as complete 
cessation of the airflow ≥ 10 s. Hypopnea was 
considered as 50% decrease in any of 3 respira-
tory signals (airflow signal, chest or abdominal 
signals) or a ≥ 1% decrease in the oxygen satu-
ration accompanied by arousal periods. Apnea/
hypopnea index (AHI) was determined via careful 
calculations. 
Echocardiographic examination
After PSG was completed, transthoracic echo- 
cardiographic examination was performed by 
a cardiologist who was blind to the results of 
PSG. LV diameters, interventricular septum 
(IVS) thickness, LV posterior wall thickness, and 
left atrial diameter (LAD) were measured with 
M-Mode echocardiography. LV ejection fraction 
(EF) was calculated by the modified Simpson tech-
nique. Pulsed wave Doppler was used to measure 
early (E) and late (A) transmitral diastolic flows, 
E/A ratio, and deceleration time (DT). Systolic, 
early, and late diastolic myocardial velocities were 
recorded from lateral mitral annulus by using tissue 
Doppler echocardiography.
Subjects were separated into two groups 
by their AHI (group 1: AHI < 15, and group 2: 
AHI ≥ 15). Patients were compared with respect 
to age, sex, body mass index (BMI), sleep micro-
structures, minimum O2 saturation, minimum heart 
rate, maximum heart rate, periodic leg movement 
frequency, echocardiographic results. 
Statistics
Distribution of the data was assessed by using 
one-sample Kolmogorov-Smirnov test. Continuous 
variables with normal distribution were expressed 
as mean ± SD, variables with skew distribution 
are expressed as median (minimum-maximum), 
categorical variables are expressed as percen- 
tage. For comparison of categorical variables or 
percentages we used Fisher’s exact and c2 tests. 
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Differences between numeric variables were tested 
with Student’s t-test or Mann-Whitney U-test. 
A p value below 0.05 was considered as statistically 
significant.
Results
The mean age was similar between the groups 
(44.1 ± 10.9 years in group 1 vs. 46.0 ± 9.4 years 
in group 2; p = 0.41). The number of female sub-
jects was lower in both groups, although it was 
lesser in group 2 (p = 0.04). The mean AHI was 
5.3 ± 4.5 in group 1, and 49.2 ± 24.8 in group 2 
(p < 0.001). BMI was significantly higher in patients 
with higher AHI (28.5 ± 4.2 kg/m2 in group 1 vs. 
31.4 ± 4.8 kg/m2 in group 2) (p = 0.05) (Table 1).
According to the PSG findings, minimum O2 sa-
turation in group 2 was significantly lower compa-
red to group 1 (p < 0.001). Periodic leg movement 
disorder score was markedly higher in group 2 
(p < 0.001). Assessment of sleep stages revealed 
no differences between the groups in terms of 
stage I, but stage II was longer, and stage III, IV 
and REM sleep were shorter in group 1 (Table 1). 
Transthoracic echocardiography showed sig-
nificantly increased IVS thickness and LAD in 
group 2 compared those of group 1 (p = 0.02 for 
IVS thickness, and p = 0.04 for LAD). Although 
the mean early diastolic transmitral inflow ve-
locity (E) was similar between the groups, late 
diastolic transmitral inflow velocity (A) was 
higher in group 2 (p = 0.01). E/A ratio was sig-
nificantly lower in group 2 (p = 0.01) (Fig. 1). 
There was a weak negative correlation between 
AHI and E/A ratio (r = −0.280, p = 0.01), and 
a weak positive correlation between minimum 
O2 saturation and E/A ratio (r = 0.288, p = 0.01) 
(Fig. 2). The mean E wave DT was not significantly 
Table 1. Clinical and PSG characteristics of subjects (nonparametric results are indicated with an*).
Group 1 (n = 43); mean ± SD 
[median (min–max)]
Group 2 (n = 37); mean ± SD 
[median (min–max)]
P
Sex: male/female 31/12 34/3 0.04
Age [years] 44.1 ± 10.9 46.0 ± 9.4 0.41
Body mass index [kg/m2] 28.48 ± 4.2 31.41 ± 4.8 0.05
Apnea/hypopnea index 5.3 ± 4.5 49.2 ± 24.8 < 0.001
Min O2 sat [%] 87.6 ± 6.1 70.5 ± 16.8 < 0.001
Min heart rate [bpm] 43.9 ± 10.6 47.08 ± 8.4 0.1
Max heart rate [bpm] 121.4 ± 12.4 114.8 ± 16.8 0.07
Periodic leg movement 
[movement/h]
8.5 ± 13.8 
[2.2 (0–66)]
23.1 ± 24.2 
[10.8 (0–85)]
< 0.001*
Sleep latency [min] 17.9 ± 12.9 14.6 ± 22.2 0.4
Sleep time [min] 388.7 ± 52.8 386.0 ± 48.0 0.8
Stage 1 [%] 8.8 ± 5.2 10.6 ± 6.5 0.1
Stage 2 [%] 59.2 ± 10.2 71.2 ± 8.8 < 0.001
Stage 3 [%] 3.7 ± 2.2 2.1 ± 1.9 0.001
Stage 4 [%] 15.1 ± 5.7 5.8 ± 6.0 < 0.001
Rapid eye movement [%] 13.4 ± 6.2 10.1 ± 5.5- 0.02
n = 13 n = 37
AHI ³ 15AHI < 15
2.5
2.0
1.0
1.5
0.5
0.0
E/
A
18
11
Figure 1. Boxplot graph demonstrates that E/A ratio 
is lower in patients with moderate-severe obstructive 
sleep apnea syndrome (OSAS) compared to mild OSAS 
patients and normal subjects; AHI — apnea/hypopnea 
index.
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different between the groups. These data demon-
strated that at least some indices of LV diastolic 
function acquired from transmitral inflow velocities 
were impaired in patients with higher AHI. On the 
contrary, LV systolic functions evaluated by EF 
were similar between the groups. Tissue Doppler 
echocardiographic evaluation of myocardial velo-
cities of lateral mitral annulus demonstrated that 
systolic myocardial velocities were also similar, 
while mean early diastolic myocardial velocity was 
lower in group 2 (p = 0.02) (Table 2). 
Of the biochemical parameters measured 
during fasting conditions, blood glucose, total 
cholesterol, HDL cholesterol, LDL cholesterol, 
homocysteine, BNP, CRP and fibrinogen levels did 
not differ significantly between the two groups. 
However, triglyceride levels of group 2 were sig-
nificantly higher (p = 0.05) (Table 3).
Figure 2. Scatter plo graph demonstrates that there is a weak positive correlation between nocturnal desaturation and 
E/A ratio (A), and weak negative correlation between apnea/hypopnea index (AHI) and E/A ratio (B). 
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Table 2. Echocardiography and tissue Doppler results (nonparametric results are indicated with an*).
Group (n = 43);  
mean ± SD 
[median (min–max)]
Group 2 (n = 37); 
mean ± SD 
[median (min-max)]
P
Left ventricular diastolic diameter [mm] 47.4 ± 3.8 47.5 ± 5.9 0.9
Ejection fraction [%] 66.2 ± 4.5 66.8 ± 5.6 0.11
Intraventricular septum thickness [mm] 9.5 ± 1.06 10.5 ± 1.4 0.02
Left ventricle posterior wall thickness [mm] 9.07 ± 0.8 9.4 ± 1.3 0.1
Left atrial diameter [mm] 33.8 ± 3.1 35.6 ± 4.05 0.04
Transmitral early diastolic flow (E) [cm/s] 63.1 ± 16.7 60.4 ± 14.6 0.4
Transmitral late diastolic flow (A) [cm/s] 57.1 ± 12.2 63.8 ± 12.1 0.01
E/A ratio 1.1 ± 0.3 0.9 ± 0.2 0.01
Deceleration time [ms] 189.7 ± 42.2 
[190 (117–304)]
201.8 ± 59.1 
[212 (21–327)]
0.127*
Systolic myocardial velocity from  
lateral mitral annulus [cm/s]
15.4 ± 3.7 15.5 ± 4.2 0.8
Early diastolic myocardial velocity from  
lateral mitral annulus [cm/s]
21.1 ± 5.6 18.3 ± 5.3 0.02
Late diastolic myocardial velocity from  
lateral mitral annulus [cm/s]
19.7 ± 5.7 20.2 ± 5.5 0.6
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Discussion
Our results demonstrated that OSAS patients 
with AHI greater than 15 had impaired diastolic 
functions, increased IVS thickness and left atrial 
diameter compared to patients with lower AHI 
in the absence of CV diseases (CVD) including 
hypertension. 
Cardiovascular complications of OSAS in-
clude systemic hypertension, acute myocardial 
infarction, nocturnal arrhythmias, cor pulmonale 
and sudden nocturnal death [2, 10]. In addition to 
cardiac arrhythmias, arterial hypertension secon-
dary to autonomic instability is known as one of 
the worst outcomes of OSAS [2]. 
Conflicting results have been reported from 
different studies regarding the role of OSAS in 
CVD. Some studies have described that OSAS is 
not an independent risk factor in the development 
of CV disorders [11–13]. However, other studies 
have stated that the rate of mortality is significantly 
higher in non-treated patients with AHI values over 
20 [14], and the incidence of CVD in non-treated 
patients with moderate-severe OSAS is markedly 
increased compared to normal individuals or trea-
ted patients [15]. This supports the point of view 
that OSAS is an important risk factor, particularly 
in case of hypertension and CVD [15–18]. Left 
ventricular diastolic dysfunction is a common fin-
ding in patients with hypertensive OSAS patients. 
OSAS is also a risk factor for the development of 
hypertension. Our study demonstrated that even 
in the absence hypertension and any other CVD, 
LV diastolic functional impairment and increase in 
left atrial diameters were more frequent.
It has been pointed out that hypertension, 
obesity, age, cholesterol levels, insulin resistance, 
diabetes mellitus and hypothyroidism are involved 
in development of CVD in patients with OSAS 
[11–13, 15]. The fact that our study enrolled pa-
tients without hypertension constitutes a different 
perspective compared to previous studies. Among 
the factors that may potentially stimulate CVD, 
only BMI and triglyceride levels were higher to 
a statistically significant extent in our patient 
group. There were no differences between the 
groups in terms of age, total cholesterol, HDL and 
LDL cholesterol levels, and some other markers 
including homocysteine, BNP, CRP and fibrinogen. 
Laaban et al. [17] have reported that there was 
no difference in hypertension prevalence between 
OSAS patients with and without LV dysfunction. 
However, Lavie et al. [19] have emphasized that 
OSAS affects death indirectly, most probably by 
being a risk factor for hypertension. Apart from 
these studies with differing arguments regarding 
hypertension — OSAS and CVD, OSAS is known 
to be a significant risk factor for hypertension. In 
a study by Marin et al. [15] a higher risk for deve-
loping CVD following OSAS diagnosis was reported 
for patients not diagnosed with any CVD prior to 
OSAS diagnosis. 
Recurrent hypoxemia in OSAS increases 
the release of adhesion molecules and enhances 
inflammatory factors such as tumor necrotizing 
factor-alpha (TNF-alpha), interleukin-6 (IL-6), CRP 
and homocysteine, while reducing the synthesis 
of the nitric oxide (NO), known as an endothelial 
vasodilator factor, leading to endothelial dysfun-
ction and development of atherosclerosis [2, 5, 
6, 20, 21]. In our study, there were no significant 
differences between the two groups in terms of 
biochemical markers such as CRP, homocysteine, 
fibrinogen, although the difference in BMI was 
significant. On the other hand, triglyceride levels 
were significantly higher in patients with OSAS 
Table 3. Comparison of biochemical values (nonparametric results are indicated with an*).
Group 1 (n = 43);  
mean ± SD
Group 2 (n = 37); 
mean ± SD
P
Fasting blood glucose [mg/dL] 90.3 ± 10.7 95.3 ± 11.6 0.06
Total cholesterol [mg/dL] 189.2 ± 41.03 196.6 ± 32.1 0.4
HDL cholesterol [mg/dL] 42.9 ± 10.1 40.7 ± 10.1 0.3
LDL cholesterol [mg/dL] 110.9 ± 35.0 113.8 ± 28.9 0.7
Triglyceride [mg/dL] 161.8 ± 97.3 214.3 ± 111.7 0.05
Homocysteine [μmol/L] 15.1±8.1 16.5 ± 12.6 0.6
B-type natriuretic peptide [pg/mL] 39.4 ± 30.7 49.7 ± 107.2 0.5
C-reactive protein [mg/dL] 4.1 ± 3.6 4.5 ± 2.7 0.5
Fibrinogen [mg/dL] 350.6 ± 86.1 336.5 ± 92.1 0.5
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(Table 3). Another significant factor in OSAS apart 
from atherogenic biochemical-metabolic changes 
is the recurrent inspiratory effort [7]. Increased 
negative intrathoracic pressure leads to rise in 
the vagal tone, and decreases LV pulse volume [7, 
13]. A study by Peker et al. [22] demonstrated an 
increased risk of developing CVD with increased 
desaturation index in patients with OSAS. From 
these perspectives, our study supports the opinion 
that LV dysfunctions due to increased intrathoracic 
pressure may occur even before nonspecific bio-
chemical changes in OSAS patients. 
Alchanatis et al. [10] determined decreased 
LV peak ejection rate, decreased LV peak filling 
rate, and delayed peak filling rate in patients with 
OSAS. Interestingly, the same study also reported 
that LV dysfunctions were not proportional with the 
severity of OSAS. This finding was most probably 
due to the low number of patients. Our results were 
consistent with those reported by Hedner et al. 
[18]. Although LV systolic function was normal in 
the moderate-severe OSAS patient group, diastolic 
dysfunction was observed both with conventional 
and tissue Doppler methods. In addition, IVS 
thickness and LAD were significantly increased 
in moderate-severe OSAS group compared to the 
mild OSAS group. It is expected that LV diastolic 
dysfunction, LV hypertrophy and increase in the 
LAD are associated with the effects of hyperten-
sion on the left ventricle. Interestingly, however, 
these changes were observed in patients without 
hypertension, suggesting that direct effect of OSAS 
may be involved in development of these changes. 
Atrial fibrillation (AF) is known to be associa-
ted with OSAS, and the connection between OSAS 
severity and the frequency of AF has been well 
established [23]. The reason for increased AF in 
OSAS could be explained by LV diastolic dysfun-
ction and increased dimensions of left atrium even 
in the absence of hypertension, as demonstrated 
in our study. Baranchuk et al. [24] have demon-
strated that continuous positive airway pressure 
treatment reverses atrial electrical remodeling 
in patients with severe OSAS. These data may 
imply the importance of early intervention in the 
treatment of OSAS.
Limitations of the study
The main limitation of our study was the 
difference of groups with respect to BMI. It wo-
uld be expected that obesity is more frequent in 
patients with higher AHI. Therefore, it seems to 
be difficult to compose the groups from patients 
with similar BMI with this kind of cross sectional 
study design. The difference of triglyceride levels 
were thought to be due to the difference of BMI. 
Another limitation was the choice of 15 arbitrarily 
as the cut-off for AHI to separate the groups. The 
reason for this cut-off value was the idea that mild 
OSAS would not have deleterious effects on heart 
independent of hypertension. 
Conclusions
In conclusion, LV diastolic dysfunction, LV hy-
pertrophy and left atrial dilatation occur in patients 
with OSAS even in the absence of hypertension. 
Left ventricular systolic function, however, is not 
affected during early period. 
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